JNJ - Is Fate Therapeutics a Buy?
The therapeutic qualities of living cells have tremendous potential to improve patient outcomes for a broad range of ailments, from cancers to autoimmune diseases. Engineering cell therapies isn't easy, and there's much left to understand and quantify when it comes to the complexity of biology, but the payoff for a successful immunotherapy is too great to ignore.
Take Fate Therapeutics (NASDAQ: FATE) as an attractive example. The early stage company has one of the most ambitious cell therapy pipelines in the industry, both in scale (counting 13 pipeline programs) and scope (spanning multiple cell types and cancers). Although investors have limited clinical data available, a recent multi-billion dollar collaboration with Johnson & Johnson (NYSE: JNJ) subsidiary Janssen might lower some of the risk involved.
Is this high-risk, high-reward pharma stock a buy?